PPCB Propanc Biopharma Net earnings per share growth forecast for next year

Corporate company logo of Propanc Biopharma Inc (PPCB)

The expected EPS growth for the coming year demonstrates the impact of Propanc Biopharma Inc (PPCB) outsourcing its production and research strategy, which reduces capital expenditures. The latest value is recorded as 0.00, confirming a shift in institutional expectations. Growth is supported by the development of a unique proenzyme therapy against cancer stem cells and strictly controlled formula delivery logistics, ensuring the continuity of clinical trials.

PPCB: Propanc Biopharma Inc. Net earnings per one share growth forecast for next year 08/16/2025 - 11/12/2026

Financial and market metric breakdowns for Propanc Biopharma (PPCB)

- share price and consensus valuation forecast:
Stock Price Propanc Biopharma Inc.|PPCB - Analyst Consensus Forecast
- market capitalization data:
Market Value Propanc Biopharma|PPCB - Value Adjusted for Debt and Cash
- company book value details:
Book Value per Share Propanc Biopharma|PPCB - Book Value of Business|Market Capitalization to Book Value Ratio propanc.com|PPCB - Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Propanc Biopharma Inc|PPCB - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Propanc Biopharma Inc.|PPCB - Company Cumulative Debt|Debts to Book Capitalization Propanc Biopharma|PPCB - Company Long-Term Indebtedness|Company Current Liabilities Propanc Biopharma|Quick Liquidity Indicator propanc.com
- earnings and valuation multiples information:
PPCB - Profit After Payment of Taxes|Projected Future Earnings Propanc Biopharma Inc|PPCB - Company Value to Net Income|Forward P/E Multiple Propanc Biopharma Inc.|PPCB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Propanc Biopharma|PPCB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Propanc Biopharma|PPCB - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months propanc.com|PPCB - Earnings per share trend in current year|Expected earnings per share growth for next year Propanc Biopharma Inc
Fundamental company analysis:Propanc Biopharma Inc, PPCB
Brand item of Propanc Biopharma

The metric is calculated as the percentage ratio of expected net earnings per share to the current value, aggregating analyst consensus forecasts. This metric determines market expectations regarding business scalability, serving as a filter against overpaying for an asset. For Propanc Biopharma Inc (PPCB), the automation of cell screening reduces costs, which is reflected in the forward-looking growth vector of EPS for the coming year.

Competing companies

GMAB (Genmab US) - Earnings growth forecast for next year|Earnings growth forecast for next year Exelixis Inc.|Net earnings per share growth forecast for next year Nuvalent, Inc. (NUVL)|KYMR (kymeratx.com) - Expected earnings per share trend next year|Earnings growth forecast for next year IDYA (IDEAYA Biosciences, Inc.)|Net earnings per one share growth forecast for next year Enliven Therapeutics Inc|ORIC Pharma - Earnings growth forecast for next year|Expected net earnings per share growth next year Relay Corp|NRIX (Nurix Therapeutics) - Expected earnings per share growth for next year|TYRA: Projected earnings per share increase next year|VSTM (Verastem) - Earnings growth forecast for next year|Expected net earnings per share growth next year Monte Rosa Therapeutics Inc GLUE|Earnings growth forecast for next year CGEM|Immuneering Corp. - Projected earnings per share growth rate for next year|C4 Therapeutics, Inc. - Expected earnings per share growth for next year|Expected earnings per share trend next year BDTX|RPTX: Expected earnings per share growth for next year|PMV Pharmaceuticals Inc. - Projected earnings per share increase next year|KPTI: Earnings growth forecast for next year|Cyclacel - Expected earnings per share trend next year|AADI (Aadi Bioscience Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Aileron ALRN|Net earnings per share growth forecast for next year Blueprint Medicines (BPMC)|GLYC (glycomimetics.com) - Expected earnings per share trend next year|Earnings growth forecast for next year SWTX (SpringWorks)